NOBILITY (2022) — Trial Summary

NOBILITY (2022): The NOBILITY trial evaluated obinutuzumab, a type II anti-CD20 monoclonal antibody, for the treatment of proliferative lupus nephritis in combination with standard therapy.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.